<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05066516</url>
  </required_header>
  <id_info>
    <org_study_id>IN_DLC_101</org_study_id>
    <nct_id>NCT05066516</nct_id>
  </id_info>
  <brief_title>The Pharmacokinetics, Safety and Tolerability of IN-C009 in Healthy Subjects</brief_title>
  <official_title>An Open-label, Randomized, Single-dose Crossover Study to Evaluate the Pharmacokinetics, Safety and Tolerability of IN-C009 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea University Anam Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea University Anam Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was conducted as a randomized, open-label, single-dose, crossover study design.&#xD;
      All participants were randomly allocated for group A (Period 1: Individual components (ICs),&#xD;
      period 2: FCDP) and group B (Period 1: FCDP, period 2: ICs), and each group was administered&#xD;
      either a single dose of IN-C009 (FCDP, dapagliflozin 10mg/linagliptin 5 mg) (HK inno.N.,&#xD;
      Seoul, Korea) or co-administration of a single dose of dapagliflozin (Forxiga 10 mg,&#xD;
      AstraZeneca, Cambridge, England, UK) and linagliptin (Trajenta 5mg, Beringer-Ingelheim,&#xD;
      Ingelheim, Germany) after at least 10 hours of overnight fasting. After the 28 days of the&#xD;
      washout period, the participants received the opposite treatment (Group A: IN-C009; Group B:&#xD;
      dapagliflozin and linagliptin). The dosage of dapagliflozin and linagliptin in the study is&#xD;
      commercially used and recommended amount for the control of T2DM currently.&#xD;
&#xD;
      On the day 1 (the day of each drug administration), the serial blood samples were drawn&#xD;
      immediately before (0 h) and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, and 72&#xD;
      h (for dapagliflozin), and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, and 72 h&#xD;
      (for linagliptin) after the each dosing to assess pharmacokinetics of each drugs.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 25, 2020</start_date>
  <completion_date type="Actual">October 18, 2020</completion_date>
  <primary_completion_date type="Actual">August 18, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>72 hours</time_frame>
    <description>peak plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>72 hours</time_frame>
    <description>area under plasma concentration versus time curve</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>72 hours</time_frame>
    <description>time at Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>half-life</measure>
    <time_frame>72 hours</time_frame>
    <description>elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL</measure>
    <time_frame>72 hours</time_frame>
    <description>clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd</measure>
    <time_frame>72 hours</time_frame>
    <description>volume distribution</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Period 1: Individual components (ICs), period 2: FCDP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Individual components (ICs), period 2: FCDP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period 1: FCDP, period 2: ICs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: FCDP, period 2: ICs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FCDP, dapagliflozin 10mg/linagliptin 5 mg or co-administration of a single dose of dapagliflozin and linagliptin</intervention_name>
    <description>FCDP, dapagliflozin 10mg/linagliptin 5 mg or ICs, co-administration of a single dose of dapagliflozin and linagliptin</description>
    <arm_group_label>Period 1: FCDP, period 2: ICs</arm_group_label>
    <arm_group_label>Period 1: Individual components (ICs), period 2: FCDP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age between 19 to 45 years;&#xD;
&#xD;
          -  body weight more than 50 kg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  a history or evidence of hepatic, renal, gastrointestinal, or hematological&#xD;
             abnormality;&#xD;
&#xD;
          -  hepatitis B, hepatitis C, syphilis, or HIV infection;&#xD;
&#xD;
          -  a history of hypersensitivity to dapagliflozin and/or linagliptin;&#xD;
&#xD;
          -  clinically significant allergic disease; alcohol or drug abuse;&#xD;
&#xD;
          -  heavy smoker (more than ten cigarettes per day);&#xD;
&#xD;
          -  use of any medication within 30 days before the start of the study that may affect the&#xD;
             study results.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 14, 2021</study_first_submitted>
  <study_first_submitted_qc>September 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2021</study_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korea University Anam Hospital</investigator_affiliation>
    <investigator_full_name>Ji-Young Park</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
    <mesh_term>Linagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

